• AK-1690: Documented Product Identity

  2026-10-19

  The supplied information identifies AK-1690 as product SKU C8937, but provides no description, mechanism, study findings, or validated application scope.

• Miconazole: Product Identity and Mechanistic Scope

  2026-10-19

  APExBIO describes Miconazole (SKU B1977) as an imidazole antifungal agent whose reported activity is linked to inhibition of ergosterol synthesis and consequent fungal cell membrane disruption. The available evidence is limited to product information: it establishes identity, stated physicochemical properties, and a mechanism-level description, but does not provide an identity-matched study, assay results, effect sizes, comparators, or model-specific evidence.

• Protoporphyrin IX: Identity, Mechanism and Evidence

  2026-10-18

  The APExBIO product page identifies Protoporphyrin IX as a heme biosynthetic pathway intermediate and describes its iron-associated conversion to heme, photodynamic properties, and relevance to porphyria. Those statements establish a biochemical and conceptual scope, but they do not provide identity-matched study data, quantitative photodynamic outcomes, clinical evidence, or evidence that a particular research study used this supplier’s material.

• SpCas9 mRNA: Identity, Mechanism and Evidence Limits

  2026-10-17

  APExBIO lists SKU R1006 as ARCA-capped, polyadenylated SpCas9 mRNA containing 5mCTP and ψUTP modifications and encoding tagged Streptococcus pyogenes Cas9. The product description supports a conceptual model in which translated Cas9, paired with a guide RNA, enables site-specific DNA double-strand break induction, but it provides no identity-matched study establishing editing efficiency, specificity, immune compatibility, or performance in a particular eukaryotic system.

• Pentostatin: Mechanism and Evidence Boundaries

  2026-10-16

  Pentostatin, also known as deoxycoformycin, is described by APExBIO as an irreversible adenosine deaminase inhibitor and immunomodulatory nucleoside analog. The product information connects adenosine deaminase inhibition with reported effects on T-cell proliferation, apoptosis, lymphocyte populations, and purine metabolism, but it does not provide an identity-matched paper, complete study methods, sample sizes, comparators, or uncertainty estimates. These claims therefore support a documented product and mechanism overview, not an independent assessment of efficacy or clinical applicability.

• SpCas9 mRNA: Identity, Mechanism and Evidence Limits

  2026-10-16

  APExBIO describes SKU R1006 as ARCA-capped, polyadenylated SpCas9 mRNA containing 5mCTP and ψUTP, two nuclear localization signals, and a C-terminal HA tag. These features define a conceptual CRISPR-Cas9 genome-editing reagent, but the available materials do not establish translation, cleavage, editing efficiency, specificity, stability, immune effects, or performance in a particular eukaryotic model.

• When Context Changes an mRNA Result

  2026-10-15

  The same Ovalbumin mRNA result can signify delivery, translation, inflammation, or antitumor immunity depending on the model and readout. The 2024 ACS Nano study illustrates why findings with mildronate-derived lipid nanoparticles should not be treated as evidence for the performance of APExBIO’s EZ Cap™ OVA mRNA, even when both involve OVA-encoding mRNA.

• SpCas9 mRNA: Identity, Mechanism and Evidence

  2026-10-15

  APExBIO describes R1006 as an ARCA-capped, polyadenylated SpCas9 mRNA containing 5mCTP and ψUTP, with two nuclear-localization signals and a C-terminal HA tag. The product information supports a conceptual role as an RNA source of Streptococcus pyogenes Cas9 for guide-directed DNA double-strand break induction, but it provides no product-matched research outcomes, quantitative performance data, or validation in a defined cell, organism, locus, or delivery context.

• L-Ornithine: Identity, Mechanism and Evidence Boundaries

  2026-10-14

  The APExBIO product description identifies L-Ornithine, or (S)-2,5-diaminopentanoic acid, as a non-proteinogenic amino acid and urea cycle intermediate associated with ornithine transcarbamylase and hepatic nitrogen disposal. The supplied material supports a documented biochemical context and product-specification summary, but it provides no identity-matched study, outcome statistics, direct performance comparison, or independent validation of the described research applications.

• TBST: Identity, Conceptual Scope and Evidence Limits

  2026-10-14

  TBST is a Tris-buffered saline formulation containing Tween 20, described by APExBIO as a buffered detergent solution for conceptual use in antibody-based assays. No matched research paper was available, so the available evidence supports product identity and intended scope, not independent claims about assay performance or biological outcomes.

• SpCas9 mRNA and Humanized Microglia Models

  2026-10-13

  A source-grounded overview of how CRISPR-generated humanized mouse models support microglia research, while distinguishing the findings of Serneels et al. from the separate product description for APExBIO SpCas9 mRNA.

• Liraglutide and the Brain–Kidney AVP Axis

  2026-10-13

  Greenwood et al. investigate how liraglutide may influence fluid homeostasis through arginine vasopressin (AVP), integrating a human before-and-after study with rat pituitary proteomics, an AVP secretion assay, and renal signaling analyses. The results support an association between liraglutide, reduced circulating AVP, sex- and time-dependent synaptic phosphorylation, and altered aquaporin 2 regulation, while leaving important causal and translational questions unresolved.

• S1P Signaling in Neuronal Injury: Evidence and Limits

  2026-10-12

  Sphingosine-1-phosphate is a context-dependent lipid messenger whose effects vary by receptor and cell type. A 2024 preclinical study associated S1P/S1PR3 signaling with neuronal apoptosis after intracerebral hemorrhage, but the findings do not establish clinical efficacy or show that S1P has a uniform biological effect.

• Chlorpromazine HCl and S. eriocheiris Cell Entry

  2026-10-12

  Wei et al. used Drosophila Schneider 2 cells to examine how Spiroplasma eriocheiris enters host cells. Their inhibitor-based results support roles for clathrin-mediated endocytosis, macropinocytosis, actin and microtubule dynamics, while leaving important questions about pathway specificity, bacterial viability and relevance to natural crustacean infection.

• Oridonin, TAA, and Bone Remodeling

  2026-10-11

  A source-grounded overview of a 2023 study examining whether oridonin could counter thioacetamide-associated bone injury by reducing osteoclast formation while supporting osteoblast differentiation. The findings are preclinical and do not establish relevance to PPM-18, clinical osteoporosis, or sepsis treatment.

8057 records 1/538 page Next 12345 下5页 Last page